Gene
GNA11
GNA11 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (10), Actionable biomarkers (3), Trial mentions (12), and 7 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
2 more sections with rows · 2 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention GNA11. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 1 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 1 of 8,738 | 0.01% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 1 of 8,275 | 0.01% | 8 of 11,460 | 0.07% |
| 2022 | 1 of 8,285 | 0.01% | 6 of 13,598 | 0.04% |
| 2021 | 1 of 8,692 | 0.01% | 8 of 15,045 | 0.05% |
| 2020 | 1 of 7,640 | 0.01% | 5 of 14,459 | 0.03% |
| 2019 | 2 of 7,300 | 0.03% | 10 of 12,159 | 0.08% |
| 2018 | 0 of 6,927 | 0.00% | 8 of 11,854 | 0.07% |
| 2017 | 0 of 6,558 | 0.00% | 9 of 11,595 | 0.08% |
Showing 10 of 37 years.
Assay-provider ledger (10)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Peter MacCallum Cancer Centre | Not a company | Clinical validation | 1 | July 01, 2025 |
| BC-BIO | Reagent supplier | Clinical validation | 1 | December 21, 2020 |
| CDI Laboratories | Reagent supplier | Clinical validationAnalytical validation | 2 | December 21, 2020 +1 undated |
| CLOUD CLONE CORP | Reagent supplier | Clinical validation | 1 | December 21, 2020 |
| CUSABIO | Reagent supplier | Clinical validation | 1 | December 21, 2020 |
Showing 5 of 10 assay-provider companies.
Actionable biomarkers (3)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| GNA11 (Q209L,Q209P) | Pi3k Pathway Inhibitor + Mek Inhibitors | response-associated | cutaneous melanoma | Cancer Genome Interpreter |
| GNA11 (Q209L,Q209P) | VORINOSTAT | response-associated | cutaneous melanoma | Cancer Genome Interpreter |
| GNA11 (Q209L,Q209P) | Selumetinib | response-associated | cutaneous melanoma | Cancer Genome Interpreter |
Trial mentions (12)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT05179174 | Trial biospecimen (AACT) |
| NCT01328106 | Trial eligibility (AACT) |
| NCT04439357 | Trial eligibility (AACT) |
| NCT03919292 | Trial eligibility (AACT) |
| NCT05239221 | Trial eligibility (AACT) |
Showing 5 of 12 trial mentions.
Target-disease associations (415)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Aagenaes syndrome | endocrine system disease | Mouse knockout (IMPC) |
| Adult-onset autosomal recessive sideroblastic anemia | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Albinism-deafness syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Alpha-thalassemia | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Alpha-thalassemia - intellectual disability syndrome linked to chromosome 16 | genetic, familial or congenital disease | Mouse knockout (IMPC) |
Showing 5 of 415 associations.
Vendor sourcing (45)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Alexion Pharmaceuticals (United States) | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | * Parts A and B: 1. Clinically significant abnormal lab values, as judged by the investigator 2. Using tobacco products with 3 months prior to first d... | View trial NCT05239221 |
| Alexion Pharmaceuticals (United States) | Trial sponsor | Mentioned in trial textTrial free-text mention | GNA11 | View trial NCT05239221 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.835C>G (p.L279V) alteration is located in exon 6 (coding exon 6) of the GNA11 gene. This alteration results from a C to G substitution at nucleotide po... | View ClinVar record SCV003575682.2 |
| Amolyt Pharma | Trial collaborator | Named in trial exclusion criteriaTrial eligibility criteria | * Parts A and B: 1. Clinically significant abnormal lab values, as judged by the investigator 2. Using tobacco products with 3 months prior to first d... | View trial NCT05239221 |
| Amolyt Pharma | Trial collaborator | Mentioned in trial textTrial free-text mention | GNA11 | View trial NCT05239221 |
Showing 5 of 45 sourcing records.
Trial-cited literature (87)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Sorafenib as first-line therapy for metastatic uveal melanoma: A multicenter, placebo-controlled randomized discontinuation study (STREAM). | iScience | 2025 | 1 |
| Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. | Nature medicine | 2023 | 73 |
| Preliminary results of the European multicentric phase III trial regarding sirolimus in slow-flow vascular malformations. | JCI insight | 2023 | 57 |
| Trametinib in Patients With <i>NF1-</i>, <i>GNAQ-</i>, or <i>GNA11</i>-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2. | JCO precision oncology | 2023 | 23 |
| Circulating Tumor DNA as a Prognostic Factor in Patients With Resectable Hepatic Metastases of Uveal Melanoma. | Annals of surgery | 2023 | 16 |
Showing 5 of 87 papers.
Protein variant mentions (8)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.F295L | 1 | 2015 | PMID 25741868 |
| p.I63V | 1 | 2010 | PMID 21083380 |
| p.R183C | 3 | 2010 to 2018 | PMID 29990500, PMID 25741868, PMID 21083380 |
| p.R60C | 1 | 2015 | PMID 25741868 |
| p.R60L | 1 | 2022 | PMID 35323929 |
Showing 5 of 8 variants.
Human sample screening reference (4)
Shown in this order: alphabetical by variant.
| Variant | GDC project | Disease / site | Affected cases | Profiled cases | Observed frequency | 95% interval |
|---|---|---|---|---|---|---|
| p.R183C | HCMI-CMDC | Ductal and Lobular Neoplasms; Complex Mixed and Stromal Neoplasms; Blood Vessel Tumors; Fibromatous Neoplasms; Epithelial Neoplasms, NOS; Mature T- and NK-Cell Lymphomas; Transitional Cell Papillomas and Carcinomas; Complex Epithelial Neoplasms; Squamous Cell Neoplasms; Soft Tissue Tumors and Sarcomas, NOS; Lymphoid Leukemias; Cystic, Mucinous and Serous Neoplasms; Gliomas; Myomatous Neoplasms; Neuroepitheliomatous Neoplasms; Malignant Lymphomas, NOS or Diffuse; Acinar Cell Neoplasms; Osseous and Chondromatous Neoplasms; Synovial-like Neoplasms; Miscellaneous Bone Tumors; Nevi and Melanomas; Adenomas and Adenocarcinomas; Other and unspecified parts of tongue; Stomach; Bronchus and lung; Larynx; Uterus, NOS; Kidney; Esophagus; Other and ill-defined sites; Skin; Colon; Thyroid gland; Bladder; Adrenal gland; Eye and adnexa; Gallbladder; Connective, subcutaneous and other soft tissues; Rectosigmoid junction; Breast; Pancreas; Small intestine; Corpus uteri; Other and unspecified parts of mouth; Liver and intrahepatic bile ducts; Nasal cavity and middle ear; Hematopoietic and reticuloendothelial systems; Brain; Other and unspecified parts of biliary tract; Bones, joints and articular cartilage of other and unspecified sites; Rectum; Unknown; Lymph nodes; Ovary | 1 | 606 | 0.17% | 0.03% to 0.93% |
| p.R183C | TCGA-LUAD | Cystic, Mucinous and Serous Neoplasms; Ductal and Lobular Neoplasms; Acinar Cell Neoplasms; Adenomas and Adenocarcinomas; Bronchus and lung | 1 | 573 | 0.17% | 0.03% to 0.98% |
| p.R183C | TCGA-SKCM | Nevi and Melanomas; Skin; Connective, subcutaneous and other soft tissues; Lymph nodes; Nasal cavity and middle ear; Vulva; Breast; Bones, joints and articular cartilage of other and unspecified sites; Retroperitoneum and peritoneum; Vagina; Colon; Adrenal gland; Corpus uteri; Other and ill-defined sites; Liver and intrahepatic bile ducts; Anus and anal canal; Spinal cord, cranial nerves, and other parts of central nervous system; Small intestine; Bronchus and lung; Brain; Parotid gland | 1 | 470 | 0.21% | 0.04% to 1.20% |
| p.R183C | TCGA-UVM | Nevi and Melanomas; Paragangliomas and Glomus Tumors; Eye and adnexa | 1 | 80 | 1.25% | 0.22% to 6.75% |
Literature-extracted relations (12)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Glioblastoma | Disease | associate |
Trametinib in Patients With <i>NF1-</i>, <i>GNAQ-</i>, or <i>GNA11</i>-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2. | 2023 |
| Melanoma | Disease | associate |
Trametinib in Patients With <i>NF1-</i>, <i>GNAQ-</i>, or <i>GNA11</i>-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2. | 2023 |
| Neoplasms | Disease | associate |
Trametinib in Patients With <i>NF1-</i>, <i>GNAQ-</i>, or <i>GNA11</i>-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2. | 2023 |
| Neoplasms | Disease | associate |
Circulating Tumor DNA as a Prognostic Factor in Patients With Resectable Hepatic Metastases of Uveal Melanoma. | 2023 |
| Uterine Cervical Neoplasms | Disease | associate |
Dynamic analysis of circulating tumor DNA to predict prognosis and monitor therapeutic response in metastatic relapsed cervical cancer. | 2021 |
Showing 5 of 12 relation assertions.
Organizations publishing (145)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 10 | 2014 to 2023 |
| Mass General Brigham | Hospital | 6 | 2015 to 2023 |
| Memorial Sloan Kettering Cancer Center | Hospital | 6 | 2014 to 2022 |
| Vanderbilt Health | Industry | 6 | 2012 to 2022 |
| Dana-Farber Cancer Institute | Other | 5 | 2016 to 2020 |
Showing 5 of 145 organizations.
Where GNA11 appears
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
392 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions and fda biomarker qualification projects.